SK117399A3 - Pyrazine compounds, preparation method thereof, pharmaceutical composition containing them and their use - Google Patents
Pyrazine compounds, preparation method thereof, pharmaceutical composition containing them and their use Download PDFInfo
- Publication number
- SK117399A3 SK117399A3 SK1173-99A SK117399A SK117399A3 SK 117399 A3 SK117399 A3 SK 117399A3 SK 117399 A SK117399 A SK 117399A SK 117399 A3 SK117399 A3 SK 117399A3
- Authority
- SK
- Slovakia
- Prior art keywords
- pyrazine
- compound
- formula
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704275.8A GB9704275D0 (en) | 1997-03-01 | 1997-03-01 | Pharmacologically active compound |
| GBGB9708183.0A GB9708183D0 (en) | 1997-04-23 | 1997-04-23 | Pharmacologically active compound |
| PCT/EP1998/001077 WO1998038174A1 (en) | 1997-03-01 | 1998-02-26 | Pyrazine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK117399A3 true SK117399A3 (en) | 2000-06-12 |
Family
ID=26311097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1173-99A SK117399A3 (en) | 1997-03-01 | 1998-02-26 | Pyrazine compounds, preparation method thereof, pharmaceutical composition containing them and their use |
Country Status (46)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420354B1 (en) | 1998-06-08 | 2002-07-16 | Advanced Medicine, Inc. | Sodium channel drugs and uses |
| GB9818881D0 (en) | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
| GB9907965D0 (en) * | 1999-04-09 | 1999-06-02 | Glaxo Group Ltd | Medical use |
| US6479498B1 (en) | 1999-06-04 | 2002-11-12 | Theravance, Inc. | Sodium channel drugs and uses |
| WO2001060806A2 (en) * | 2000-02-16 | 2001-08-23 | Neurogen Corporation | Substituted arylpyrazines |
| EP1500653A1 (en) * | 2000-02-16 | 2005-01-26 | Neurogen Corporation | Substituted arylpyrazines |
| GB0010971D0 (en) * | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Process |
| GB0016040D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1446387B1 (en) * | 2001-11-21 | 2009-11-04 | Pharmacia & Upjohn Company LLC | Substituted aryl 1,4-pyrazine derivatives |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| EP1458386B1 (en) * | 2001-12-27 | 2007-04-18 | Ortho-McNeil Pharmaceutical, Inc. | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| JP2005533014A (ja) | 2002-04-26 | 2005-11-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 置換ピラジン誘導体 |
| CA2496197A1 (en) | 2002-08-20 | 2004-03-04 | Neurogen Corporation | 5-substituted-2-arylpyrazines as modulators of crf receptors |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| CA2514574A1 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
| TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| CA2595855C (en) | 2005-01-25 | 2017-07-04 | Synta Pharmaceuticals Corp. | Pyrazine compounds for inflammation and immune-related uses |
| MX2007009923A (es) * | 2005-02-15 | 2008-03-04 | Jazz Pharmaceuticals | Forma farmaceutica y metodo para liberacion sostenida de un compuesto de pirazina sustituido. |
| NL2000284C2 (nl) * | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| WO2007083239A1 (en) * | 2006-01-23 | 2007-07-26 | Pfizer Limited | Pyridine derivatives as sodium channel modulators |
| CA2685952C (en) * | 2007-05-03 | 2012-03-13 | Pfizer Limited | N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| GB0800741D0 (en) | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| FR3001151B1 (fr) | 2013-01-21 | 2016-04-08 | Pf Medicament | Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| CN108101857B (zh) * | 2016-11-24 | 2021-09-03 | 韶远科技（上海)有限公司 | 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺 |
| CN107011273A (zh) * | 2017-05-04 | 2017-08-04 | 无锡捷化医药科技有限公司 | 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法 |
| CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN115611700A (zh) * | 2022-10-11 | 2023-01-17 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4402958A (en) * | 1981-11-19 | 1983-09-06 | American Cyanamid Company | Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates |
| DE3873812D1 (de) | 1987-04-07 | 1992-09-24 | Ciba Geigy Ag | 3h-1,2,3-triazolo(4,5-d)pyrimidine. |
| JPH08238778A (ja) * | 1995-03-07 | 1996-09-17 | Brother Ind Ltd | インク噴射装置の電極形成方法 |
-
1998
- 1998-02-23 MA MA24973A patent/MA26473A1/fr unknown
- 1998-02-24 PE PE1998000134A patent/PE58299A1/es not_active Application Discontinuation
- 1998-02-26 EA EA199900687A patent/EA002102B1/ru not_active IP Right Cessation
- 1998-02-26 EE EEP199900376A patent/EE9900376A/xx unknown
- 1998-02-26 ES ES98913592T patent/ES2205469T3/es not_active Expired - Lifetime
- 1998-02-26 AU AU68237/98A patent/AU732915B2/en not_active Ceased
- 1998-02-26 US US09/380,062 patent/US6255307B1/en not_active Expired - Fee Related
- 1998-02-26 JP JP53731098A patent/JP3369189B2/ja not_active Expired - Fee Related
- 1998-02-26 NZ NZ337121A patent/NZ337121A/xx not_active IP Right Cessation
- 1998-02-26 SI SI9830578T patent/SI0966448T1/xx unknown
- 1998-02-26 HU HU0001802A patent/HU225852B1/hu not_active IP Right Cessation
- 1998-02-26 GT GT199800046A patent/GT199800046A/es unknown
- 1998-02-26 MY MYPI98000852A patent/MY118612A/en unknown
- 1998-02-26 PL PL335441A patent/PL192864B1/pl unknown
- 1998-02-26 BR BRPI9807814-3A patent/BR9807814B1/pt not_active IP Right Cessation
- 1998-02-26 WO PCT/EP1998/001077 patent/WO1998038174A1/en active IP Right Grant
- 1998-02-26 EP EP98913592A patent/EP0966448B1/en not_active Expired - Lifetime
- 1998-02-26 JO JO19982035A patent/JO2035B1/en active
- 1998-02-26 SK SK1173-99A patent/SK117399A3/sk unknown
- 1998-02-26 IL IL13129398A patent/IL131293A/xx not_active IP Right Cessation
- 1998-02-26 AT AT98913592T patent/ATE251143T1/de active
- 1998-02-26 CN CN98804593A patent/CN1105111C/zh not_active Expired - Fee Related
- 1998-02-26 PT PT98913592T patent/PT966448E/pt unknown
- 1998-02-26 TR TR1999/02082T patent/TR199902082T2/xx unknown
- 1998-02-26 CA CA002282585A patent/CA2282585C/en not_active Expired - Fee Related
- 1998-02-26 YU YU40799A patent/YU40799A/sh unknown
- 1998-02-26 CO CO98010500A patent/CO4950513A1/es unknown
- 1998-02-26 GE GEAP19984976A patent/GEP20012555B/en unknown
- 1998-02-26 KR KR1019997007937A patent/KR100544263B1/ko not_active IP Right Cessation
- 1998-02-26 CZ CZ19993111A patent/CZ295618B6/cs not_active IP Right Cessation
- 1998-02-26 ID IDW990951A patent/ID22850A/id unknown
- 1998-02-26 DE DE69818643T patent/DE69818643T2/de not_active Expired - Lifetime
- 1998-02-26 DK DK98913592T patent/DK0966448T3/da active
- 1998-02-26 AP AP9901632A patent/AP9901632A0/xx unknown
- 1998-02-27 PA PA19988448201A patent/PA8448201A1/es unknown
- 1998-02-27 AR ARP980100906A patent/AR011174A1/es active IP Right Grant
- 1998-02-27 HN HN1998000036A patent/HN1998000036A/es unknown
- 1998-02-27 UY UY24911A patent/UY24911A1/es unknown
- 1998-02-27 SV SV1998000029A patent/SV1998000029A/es not_active Application Discontinuation
- 1998-02-27 HR HR9708183.0A patent/HRP980107A2/hr not_active Application Discontinuation
- 1998-03-03 TW TW087103079A patent/TW513416B/zh not_active IP Right Cessation
-
1999
- 1999-02-11 HN HN1999000019A patent/HN1999000019A/es unknown
- 1999-08-24 IS IS5163A patent/IS5163A/is unknown
- 1999-08-27 OA OA9900196A patent/OA11151A/en unknown
- 1999-08-31 NO NO19994213A patent/NO313383B1/no not_active IP Right Cessation
- 1999-09-09 BG BG103723A patent/BG103723A/bg unknown
-
2000
- 2000-04-10 HK HK00102173A patent/HK1023116A1/xx not_active IP Right Cessation
-
2001
- 2001-05-16 US US09/855,703 patent/US6599905B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK117399A3 (en) | Pyrazine compounds, preparation method thereof, pharmaceutical composition containing them and their use | |
| EP1650205B1 (en) | Cyclohexanecarboxylic acid compound | |
| US6503909B1 (en) | Pyrazine compounds | |
| CN107438604B (zh) | 新吡啶化合物 | |
| JP2002509930A (ja) | ベンゾ複素環ジスタマイシン誘導体、その製造方法および抗腫瘍薬としてのそれの使用 | |
| EP3700890B1 (en) | Alcoxyamino derivatives for treating pain and pain related conditions | |
| SK9592000A3 (en) | Triazine compounds for treatment of cns disorders | |
| US4609659A (en) | 2,6-disubstituted derivatives of 3-nitropyrazines useful as adjuncts to radiation therapy | |
| JP2002517494A (ja) | シンナモイルジスタマイシン類似誘導体、その製造方法及びその抗腫瘍剤としての使用 | |
| EP0111151B1 (en) | Substituted nitropyrazine compounds, process for their preparation and pharmaceutical compositions containing them | |
| NZ233928A (en) | 1,2,4-triazolo(4,3-a)pyrazine derivatives and anticonvulsant compositions | |
| EP0792879A1 (en) | Hydrate for medicinal use | |
| JP2002308773A (ja) | ピラジン化合物 | |
| JPH09132560A (ja) | ２−シアノ−３−メルカプトクロトンアミド | |
| CN117586204A (zh) | 异硒唑酮类化合物、其合成方法及用途 | |
| CN112851599A (zh) | 一种具有双阳离子季铵盐结构的化合物及其制备方法和用途 | |
| MXPA99007910A (es) | Compuestos de pirazina | |
| KR20050019935A (ko) | 피라진 화합물을 포함하는 제약 조성물 | |
| MXPA01001983A (es) | Compuestos de pirazina | |
| CZ20002361A3 (cs) | Triazinové deriváty |